ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA

10 May 2011

• By The Pink Sheet Daily

DDMAC says that there is no expanded access program for the unapproved leukemia drug Omapro (omacetaxine mepesuccinate), but even if there were one, ChemGenex would not be allowed to promote it.

ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA

More from Archive

More from Pink Sheet